Nektar Therapeutics Announces Publication of Results from Phase 1 Dose-Escalation Study for Bempega | EXEL Message Board Posts

EXEL   /  Message Board  /  Read Message

 

 






Keyword
Subject
Between
and
Rec'd By
Authored By
Minimum Recs
  
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board
Msg  24678 of 24955  at  5/22/2020 7:56:02 PM  by

Pacific


 In response to msg 24675 by  mathlover
view thread

Re: Nektar Therapeutics Announces Publication of Results from Phase 1 Dose-Escalation Study for Bempegaldesleukin Plus Nivolumab in 'Cancer Discovery' Journal

“NKTR-214 and Nivo combo cannot provide stronger benefits as compared to current IO-TKI combos in RCC”

How are you determining that? 1L RCC ORR was 71.4% (10/14; 7.1% CR, 64.3% PR) and ORR of 28.6% (2/7, all PRs) in 2L I-O naive pts. It’s early data, with small n.

Total ORR was 59.5%, CR was 18.9%, and DCR 83.8%
ORR in PD-L1+ and PD-L1- patients was respectively 64.7% and 50.0%



     e-mail to a friend      printer-friendly     add to library      
| More
Recs: 2     Views: 250
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board

Replies
Msg # Subject Author Recs Date Posted
24680 Re: Nektar Therapeutics Announces Publication of Results from Phase 1 Dose-Escalation Study for Bempegaldesleukin Plus Nivolumab in 'Cancer Discovery' Journal mathlover 3 5/22/2020 9:16:12 PM






About Us  •  Contact Us  •  Follow Us on Twitter  •  Members Directory  •  Help Center  •  Advertise
Not a member yet? What are you waiting for? Create Account
Want to contribute? Support InvestorVillage by donating
© 2003-2019 Investorvillage.com. All rights reserved. User Agreement
   
Financial Market Data provided by
.


Loading...